14 Citations (Scopus)

Abstract

The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N = 30), or <5 years of remission (early relapse, N = 132), were compared. The late relapsing patients had better prognostic characteristics at diagnosis, such as stage I/II disease (73% vs. 49%, P = 0.04), a normal lactic dehydrogenase (77% vs. 48%, P = 0.01), and a Karnofsky performance score of ≥80 (100% vs. 86%, P = 0.01). The 3-year survival after relapse was better in late relapsing patients (48% vs. 25%, P = 0.03), but the survival at 5 years (32% vs. 20%) and 10 years (13% vs. 14%) after relapse was not different. A multivariate analysis of factors predicting survival after relapse found age (P < 0.0001) and presence of B-symptoms (P = 0.03) to predict survival, but not early versus late relapse. A small percentage of the late relapsing patients can have a prolonged second remission. However, the overall survival from the time of relapse was not different between early and late relapsing patients with most succumbing to lymphoma.

Original languageEnglish (US)
Pages (from-to)354-358
Number of pages5
JournalBritish Journal of Haematology
Volume151
Issue number4
DOIs
StatePublished - Nov 1 2010

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Recurrence
Survival
Vincristine
Prednisolone
Doxorubicin
Cyclophosphamide
Lymphoma
Oxidoreductases
Milk
Multivariate Analysis

Keywords

  • Diffuse large B-cell lymphoma (DLBC)
  • Late relapse
  • Lymphoma
  • Non-Hodgkin Lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Late relapse in patients with diffuse large B-cell lymphoma. / Vose, Julie Marie; Weisenburger, Dennis D.; Loberiza, Fausto R.; Arevalo, Alejandro; Bast, Martin; Armitage, Joel D; Bierman, Philip Jay; Bociek, Robert G; Armitage, James Olen.

In: British Journal of Haematology, Vol. 151, No. 4, 01.11.2010, p. 354-358.

Research output: Contribution to journalArticle

Vose, Julie Marie ; Weisenburger, Dennis D. ; Loberiza, Fausto R. ; Arevalo, Alejandro ; Bast, Martin ; Armitage, Joel D ; Bierman, Philip Jay ; Bociek, Robert G ; Armitage, James Olen. / Late relapse in patients with diffuse large B-cell lymphoma. In: British Journal of Haematology. 2010 ; Vol. 151, No. 4. pp. 354-358.
@article{f3b6d3eaf9584839bfac765d2cc19127,
title = "Late relapse in patients with diffuse large B-cell lymphoma",
abstract = "The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N = 30), or <5 years of remission (early relapse, N = 132), were compared. The late relapsing patients had better prognostic characteristics at diagnosis, such as stage I/II disease (73{\%} vs. 49{\%}, P = 0.04), a normal lactic dehydrogenase (77{\%} vs. 48{\%}, P = 0.01), and a Karnofsky performance score of ≥80 (100{\%} vs. 86{\%}, P = 0.01). The 3-year survival after relapse was better in late relapsing patients (48{\%} vs. 25{\%}, P = 0.03), but the survival at 5 years (32{\%} vs. 20{\%}) and 10 years (13{\%} vs. 14{\%}) after relapse was not different. A multivariate analysis of factors predicting survival after relapse found age (P < 0.0001) and presence of B-symptoms (P = 0.03) to predict survival, but not early versus late relapse. A small percentage of the late relapsing patients can have a prolonged second remission. However, the overall survival from the time of relapse was not different between early and late relapsing patients with most succumbing to lymphoma.",
keywords = "Diffuse large B-cell lymphoma (DLBC), Late relapse, Lymphoma, Non-Hodgkin Lymphoma",
author = "Vose, {Julie Marie} and Weisenburger, {Dennis D.} and Loberiza, {Fausto R.} and Alejandro Arevalo and Martin Bast and Armitage, {Joel D} and Bierman, {Philip Jay} and Bociek, {Robert G} and Armitage, {James Olen}",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1365-2141.2010.08330.x",
language = "English (US)",
volume = "151",
pages = "354--358",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Late relapse in patients with diffuse large B-cell lymphoma

AU - Vose, Julie Marie

AU - Weisenburger, Dennis D.

AU - Loberiza, Fausto R.

AU - Arevalo, Alejandro

AU - Bast, Martin

AU - Armitage, Joel D

AU - Bierman, Philip Jay

AU - Bociek, Robert G

AU - Armitage, James Olen

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N = 30), or <5 years of remission (early relapse, N = 132), were compared. The late relapsing patients had better prognostic characteristics at diagnosis, such as stage I/II disease (73% vs. 49%, P = 0.04), a normal lactic dehydrogenase (77% vs. 48%, P = 0.01), and a Karnofsky performance score of ≥80 (100% vs. 86%, P = 0.01). The 3-year survival after relapse was better in late relapsing patients (48% vs. 25%, P = 0.03), but the survival at 5 years (32% vs. 20%) and 10 years (13% vs. 14%) after relapse was not different. A multivariate analysis of factors predicting survival after relapse found age (P < 0.0001) and presence of B-symptoms (P = 0.03) to predict survival, but not early versus late relapse. A small percentage of the late relapsing patients can have a prolonged second remission. However, the overall survival from the time of relapse was not different between early and late relapsing patients with most succumbing to lymphoma.

AB - The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N = 30), or <5 years of remission (early relapse, N = 132), were compared. The late relapsing patients had better prognostic characteristics at diagnosis, such as stage I/II disease (73% vs. 49%, P = 0.04), a normal lactic dehydrogenase (77% vs. 48%, P = 0.01), and a Karnofsky performance score of ≥80 (100% vs. 86%, P = 0.01). The 3-year survival after relapse was better in late relapsing patients (48% vs. 25%, P = 0.03), but the survival at 5 years (32% vs. 20%) and 10 years (13% vs. 14%) after relapse was not different. A multivariate analysis of factors predicting survival after relapse found age (P < 0.0001) and presence of B-symptoms (P = 0.03) to predict survival, but not early versus late relapse. A small percentage of the late relapsing patients can have a prolonged second remission. However, the overall survival from the time of relapse was not different between early and late relapsing patients with most succumbing to lymphoma.

KW - Diffuse large B-cell lymphoma (DLBC)

KW - Late relapse

KW - Lymphoma

KW - Non-Hodgkin Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=77958572497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958572497&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08330.x

DO - 10.1111/j.1365-2141.2010.08330.x

M3 - Article

C2 - 20880118

AN - SCOPUS:77958572497

VL - 151

SP - 354

EP - 358

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -